Literature DB >> 8904633

The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor.

A Parenti1, S Donnini, L Morbidelli, H J Granger, M Ziche.   

Abstract

In order to assess the mechanism of action of the quinoline-3-carboxyamide linomide as an antiangiogenic drug, the effect of linomide was studied in vitro on postcapillary endothelial cells exposed to vascular endothelial growth factor (VEGF). Linomide did not block the spontaneous replication of endothelial cells, but significantly suppressed endothelial cell growth and migration elicited by VEGF. It is concluded that linomide appears to be an effective tool to inhibit VEGF-dependent angiogenesis.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8904633      PMCID： PMC1915758          DOI： 10.1111/j.1476-5381.1996.tb15718.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  9 in total

Review 1.  Molecular and biological properties of the vascular endothelial growth factor family of proteins.

Authors:  N Ferrara; K Houck; L Jakeman; D W Leung
Journal:  Endocr Rev       Date:  1992-02       Impact factor: 19.871

2.  Venular endothelial cells from bovine heart.

Authors:  M E Schelling; C J Meininger; J R Hawker; H J Granger
Journal:  Am J Physiol       Date:  1988-06

Review 3.  Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1995-12-28       Impact factor: 91.245

4.  Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium.

Authors:  L Morbidelli; C H Chang; J G Douglas; H J Granger; F Ledda; M Ziche
Journal:  Am J Physiol       Date:  1996-01

5.  The tachykinin NK1 receptor mediates the migration-promoting effect of substance P on human skin fibroblasts in culture.

Authors:  A Parenti; S Amerini; F Ledda; C A Maggi; M Ziche
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

6.  Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator.

Authors:  T Kalland; G Alm; T Stålhandshe
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

7.  Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.

Authors:  J Vukanovic; J T Isaacs
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

8.  Antiangiogenic effects of the quinoline-3-carboxamide linomide.

Authors:  J Vukanovic; A Passaniti; T Hirata; R J Traystman; B Hartley-Asp; J T Isaacs
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

9.  Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers.

Authors:  J Vukanovic; J T Isaacs
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701
  9 in total
  4 in total

1.  Anticancer effects of the engineered stem cells transduced with therapeutic genes via a selective tumor tropism caused by vascular endothelial growth factor toward HeLa cervical cancer cells.

Authors:  Hye-Sun Kim; Bo-Rim Yi; Kyung-A Hwang; Seung U Kim; Kyung-Chul Choi
Journal:  Mol Cells       Date:  2013-09-02       Impact factor: 5.034

Review 2.  The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.

Authors:  John T Isaacs
Journal:  Expert Opin Investig Drugs       Date:  2010-10       Impact factor: 6.206

3.  Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex.

Authors:  Pia Lindberg; Anita Billström; Bertil Kinnby
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

4.  Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants.

Authors:  M Ziche; S Donnini; L Morbidelli; A Parenti; G Gasparini; F Ledda
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.